- Home
- MIRM vs MRUS Comparison
MIRM vs MRUS Comparison
Compare MIRM & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- MRUS
- Stock Information
- Founded
- MIRM 2018
- MRUS 2003
- Country
- MIRM United States
- MRUS Netherlands
- Employees
- MIRM N/A
- MRUS N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- MIRM Health Care
- MRUS Health Care
- Exchange
- MIRM Nasdaq
- MRUS Nasdaq
- Market Cap
- MIRM 2.5B
- MRUS 2.8B
- IPO Year
- MIRM 2019
- MRUS 2016
- Fundamental
- Price
- MIRM $52.45
- MRUS $47.37
- Analyst Decision
- MIRM Strong Buy
- MRUS Strong Buy
- Analyst Count
- MIRM 11
- MRUS 13
- Target Price
- MIRM $57.00
- MRUS $85.67
- AVG Volume (30 Days)
- MIRM 504.4K
- MRUS 513.2K
- Earning Date
- MIRM 02-26-2025
- MRUS 02-26-2025
- Dividend Yield
- MIRM N/A
- MRUS N/A
- EPS Growth
- MIRM N/A
- MRUS N/A
- EPS
- MIRM N/A
- MRUS N/A
- Revenue
- MIRM $307,028,000.00
- MRUS $35,932,000.00
- Revenue This Year
- MIRM $83.04
- MRUS N/A
- Revenue Next Year
- MIRM $27.22
- MRUS $42.15
- P/E Ratio
- MIRM N/A
- MRUS N/A
- Revenue Growth
- MIRM 112.14
- MRUS N/A
- 52 Week Low
- MIRM $23.14
- MRUS $37.77
- 52 Week High
- MIRM $54.23
- MRUS $61.61
- Technical
- Relative Strength Index (RSI)
- MIRM 64.07
- MRUS 71.36
- Support Level
- MIRM $51.02
- MRUS $39.67
- Resistance Level
- MIRM $53.76
- MRUS $41.15
- Average True Range (ATR)
- MIRM 2.04
- MRUS 1.71
- MACD
- MIRM 0.03
- MRUS 0.86
- Stochastic Oscillator
- MIRM 73.31
- MRUS 91.57
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.